J
John Doukas
Researcher at Harvard University
Publications - 17
Citations - 1410
John Doukas is an academic researcher from Harvard University. The author has contributed to research in topics: Proto-oncogene tyrosine-protein kinase Src & Vascular permeability. The author has an hindex of 13, co-authored 17 publications receiving 1343 citations. Previous affiliations of John Doukas include Brigham and Women's Hospital & Boston University.
Papers
More filters
Journal ArticleDOI
Efficacy of TG101348, a Selective JAK2 Inhibitor, in Treatment of a Murine Model of JAK2V617F-Induced Polycythemia Vera
Gerlinde Wernig,Michael G. Kharas,Rachel Okabe,Sandra A. Moore,Dena S. Leeman,Dana E. Cullen,Maricel Gozo,Elizabeth McDowell,Ross L. Levine,Ross L. Levine,John Doukas,Chi Ching Mak,Glenn Noronha,Michael Martin,Yon D. Ko,Benjamin H. Lee,Richard M. Soll,Ayalew Tefferi,John Hood,D. Gary Gilliland,D. Gary Gilliland,D. Gary Gilliland +21 more
TL;DR: In this article, a small-molecule inhibitor of JAK2 with an in vitro IC50 of approximately 3 nM was used to treat myeloproliferative disease induced by the JAK 2V617F mutation.
Journal ArticleDOI
Src blockade stabilizes a Flk/cadherin complex, reducing edema and tissue injury following myocardial infarction
Sara M. Weis,Satoshi Shintani,Alberto Weber,Rudolf Kirchmair,Malcolm R. Wood,Adrianna Cravens,Heather McSharry,Atsushi Iwakura,Young Sup Yoon,Nathan Himes,Deborah Burstein,John Doukas,Richard M. Soll,Douglas W. Losordo,David A. Cheresh +14 more
TL;DR: A molecular mechanism to account for the Src requirement in VEGF-mediated permeability is defined and provided a basis for Src inhibition as a therapeutic option for patients with acute MI.
Journal ArticleDOI
Phosphoinositide 3-kinase γ/δ inhibition limits infarct size after myocardial ischemia/reperfusion injury
John Doukas,Wolfgang Wrasidlo,Glenn Noronha,Elena Dneprovskaia,Richard E. Fine,Sara M. Weis,John Hood,Anthony DeMaria,Richard M. Soll,David A. Cheresh +9 more
TL;DR: By targeting pathologic events occurring relatively late in myocardial damage, a potential means of addressing an elusive clinical goal: meaningful cardioprotection in the postreperfusion time period is identified.
Journal ArticleDOI
Retinal vascular permeability suppression by topical application of a novel VEGFR2/Src kinase inhibitor in mice and rabbits.
Lea Scheppke,Edith Aguilar,R.F. Gariano,Ruth Jacobson,John Hood,John Doukas,Jon Cao,Glenn Noronha,Shiyin Yee,Sara M. Weis,Michael Martin,Richard Soll,David A. Cheresh,Martin Friedlander +13 more
TL;DR: A role for Src kinase is established in VEGF-mediated retinal vascular permeability and a potentially safe and painless topically applied therapeutic option for treating vision loss due to neovascular-associated retinal edema is established.
Journal ArticleDOI
Topical administration of a multi-targeted kinase inhibitor suppresses choroidal neovascularization and retinal edema.
John Doukas,Sankaranarayana Pillai Mahesh,Naoyasu Umeda,Shu Kachi,Hideo Akiyama,Katsutoshi Yokoi,Jon Cao,Zoe Chen,Dellamary Luis A,Betty Tam,Adrienne Racanelli-Layton,John Hood,Michael D. Martin,Glenn Noronha,Richard Soll,Peter A. Campochiaro +15 more
TL;DR: Topical TG100801 significantly suppressed laser‐induced CNV in mice, and reduced fluorescein leakage from the vasculature and retinal thickening measured by optical coherence tomography in a rat model of retinal vein occlusion, suggesting that TG 100801 may provide a new topically applied treatment approach for ocular neovascularization and retina edema.